Spinraza and Risdiplam MTA webinar : Together we are Stronger

SMA UK are proud to join together with Treat SMA and MDUK to bring you this webinar about NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam. 2024 sees the end of the managed access agreements (MAAs) for the two treatments. An expert committee will gather to assess the new clinical and real-world evidence, along with evidence from clinical trials, to decide whether the two treatments will be recommended for routine use in the NHS.
This webinar will inform you about the process, let you know about the role of the patient groups and will tell you how to get involved. We need your help to get these treatments approved.
To get involved:
Case studies/Video Clips Written: [e-mail]
Audio: WhatsApp [phone] Video:
We Transfer [e-mail]
WhatsApp [phone]
Survey
The link to the survey will be released at the end of February 2024